Electra Therapeutics is a speculative biotech with no reported margins and below-average business quality, but insiders bought about $40.0M (7.05% of market cap) in 90 days with no sales, a strong show of conviction. Price data was unavailable this run, so no trade setup exists.
Thesis pillars
- Binary Biotech Speculative Profile—
- Heavy Insider Buying Conviction—
- Strong Liquidity Cushion—
- +2 more pillars — see the Why tab for full reasoning
Electra Therapeutics, Inc. (ETRA) Stock Analysis
Healthcare · Biotechnology
DATA_ISSUE. No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run.
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart,... Read more
DATA_ISSUE. No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run. Score 5.6/10, moderate confidence.
Passes 8/10 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.60, news boost analyst cluster(5), earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-14Recent Developments — Electra Therapeutics, Inc.
Latest news
- NEWS Jefferies Initiates Coverage On Electra Therapeutics with Buy Rating, Announces Price Target of $32 — benzinga Oct 13, 2026 positive
- NEWS Evercore ISI Group Initiates Coverage On Electra Therapeutics with Outperform Rating, Announces Price Target of $36 — benzinga Oct 13, 2026 positive
- NEWS TD Cowen Initiates Coverage On Electra Therapeutics with Buy Rating — benzinga Oct 13, 2026 positive
- NEWS This Electra Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday — benzinga Oct 13, 2026 positive
Generated 2026-10-14T11:42:18Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
0Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
DATA_ISSUE. No current price available — cannot compute entry, target, or stop. Upstream data source (Alpaca/yfinance) did not return a price for this run. Target $0.00, stop $0.00, A.R:R 0.0:1. Score 5.6/10, moderate confidence.
Price unavailable this run — no trade setup.
Electra Therapeutics, Inc. trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: DATA_ISSUE.
What does Electra Therapeutics, Inc. do?Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets...
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.